Regression of Albuminuria and Hypertension and Arrest of Severe Renal Injury by a Losartan-Hydrochlorothiazide Association in a Model of Very Advanced Nephropathy
Open Access
- 19 February 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (2) , e56215
Abstract
Treatments that effectively prevent chronic kidney disease (CKD) when initiated early often yield disappointing results when started at more advanced phases. We examined the long-term evolution of renal injury in the 5/6 nephrectomy model (Nx) and the effect of an association between an AT-1 receptor blocker, losartan (L), and hydrochlorothiazide (H), shown previously to be effective when started one month after Nx. Adult male Munich-Wistar rats underwent Nx, being divided into four groups: Nx+V, no treatment; Nx+L, receiving L monotherapy; Nx+LH, receiving the L+H association (LH), and Nx+AHHz, treated with the calcium channel blocker, amlodipine, the vascular relaxant, hydralazine, and H. This latter group served to assess the effect of lowering blood pressure (BP). Rats undergoing sham nephrectomy (S) were also studied. In a first protocol, treatments were initiated 60 days after Nx, when CKD is at a relatively early stage. In a second protocol, treatments were started 120 days after Nx, when glomerulosclerosis and interstitial fibrosis are already advanced. In both protocols, L treatment promoted only partial renoprotection, whereas LH brought BP, albuminuria, tubulointerstitial cell proliferation and plasma aldosterone below pretreatment levels, and completely detained progression of renal injury. Despite normalizing BP, the AHHz association failed to prevent renal damage, indicating that the renoprotective effect of LH was not due to a systemic hemodynamic action. These findings are inconsistent with the contention that thiazides are innocuous in advanced CKD. In Nx, LH promotes effective renoprotection even at advanced stages by mechanisms that may involve anti-inflammatory and intrarenal hemodynamic effects, but seem not to require BP normalization.Keywords
This publication has 46 references indexed in Scilit:
- A Pilot Study Comparing Furosemide and Hydrochlorothiazide in Patients With Hypertension and Stage 4 or 5 Chronic Kidney DiseaseThe Journal of Clinical Hypertension, 2011
- Aldosterone mediates activation of the thiazide-sensitive Na-Cl cotransporter through an SGK1 and WNK4 signaling pathwayJournal of Clinical Investigation, 2009
- Regression of glomerulosclerosis in subtotally nephrectomized rats: effects of monotherapy with losartan, spironolactone, and their combinationAmerican Journal of Physiology-Renal Physiology, 2008
- Clinical Outcomes by Race in Hypertensive Patients With and Without the Metabolic SyndromeAntihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Archives of internal medicine (1960), 2008
- Aldosterone Stimulates Collagen Gene Expression and Synthesis Via Activation of ERK1/2 in Rat Renal FibroblastsHypertension, 2005
- An extremely high dose of losartan affords superior renoprotection in the remnant modelKidney International, 2005
- Renal expression of COX-2, ANG II, and AT1receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatoryAmerican Journal of Physiology-Renal Physiology, 2004
- Tight blood pressure control decreases apoptosis during renal damageKidney International, 2004
- Mycophenolate Mofetil Reduces Renal Injury in the Chronic Nitric Oxide Synthase Inhibition ModelHypertension, 2001
- Effects of Reduced Glomerular Filtration Rate on Responsiveness to Chlorothiazide and Mercurial DiureticsCirculation, 1961